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1. Introduction
1.1. Overview and general aspects of Zika
Zika virus (ZIKV) is a mosquito-borne flavivirus discovered in rhesus monkeys in the Zika 
close to Kampala, Uganda in 1947, but it was not until February 2016 that the World Health 
Organization (WHO) declared Zika a public health emergency [1–5]. The introduction and 
spread of ZIKV throughout Latin America embodies a convergence of ecologic, social and 
environmental factors that foster the emergence of new infectious threats in susceptible popu-
lations. Although ZIKV infection is typically asymptomatic or causes a mild flu-like, birth 
defects indicate a wide clinical spectrum that includes severe manifestations that underlie 
global concern [4–7]. These, along with evidence of non-vector-borne transmission routes such 
as vertical transmission, blood transfusion and sexual contact [8–11], highlight the need for 
augmented research in the area [12]. Currently, research efforts have been increasingly focus-
ing on disease prevention through vaccine design and understanding of the role of antibody 
disease enhancement (ADE) on the immunopathogenesis of severe cases and fetal outcomes. 
New diagnostic tools are required in order to bypass cross reactivity with other flaviviruses 
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like dengue or yellow fever, and there is a gap for implementation research in order to develop 
effective strategies for vector control and awareness programs among people [10−18].
2. Epidemiology
It is difficult to exaggerate the medical importance and burden of vector-borne infectious 
diseases as a series of emerging and re-emerging arboviruses epidemics are propagated in 
recent decades in previously unexposed geographic areas in Latin America and the Caribbean 
[9]. ZIKV has caused epidemics during 2015–2017 in different countries of the Americas, with 
more than 50 countries/territories affected in this region, and 148 globally affected in any 
form (including imported cases). After Brazil, probably Colombia is the second most affected 
country in the region, with over 100,000 cases having been reported from this northern South 
American country, reflecting overall incidence rates above 150 cases/100,000 [18]. During the 
years 2015–2017, the circulation of ZIKV was confirmed in 560 municipalities and four dis-
tricts of Colombia. Suspected cases of ZIKV disease have been reported in 245 municipalities, 
adding a total of 809 municipalities with reported cases between confirmed and suspected 
cases. Thirty-five territorial entities of the departmental and district order have notified the 
surveillance system of ZIKV [19].
Although Colombia is not currently (November 2017) at epidemic status for ZIKV, it has 
become endemic with continued transmission. The main territories affected are those with 
previous circulation of dengue and chikungunya. In this sense, the departments (at the first 
administrative level) of Valle del Cauca, Santander, Tolima, Cundinamarca and Meta account 
with more than the 60% of the cases reported during 2017. On the other hand, 238 cases of 
symptomatic ZIKV infection had been documented in pregnant women (37 confirmed cases), 
and 20 cases charted in municipalities with no previously known ZIKV transmission. By terri-
torial entity of residence, the one that has reported the largest proportion of cases is Santander 
with 46 pregnant women in the northeastern region, border with Venezuela [19].
3. Clinical aspects
It is estimated that 80% of people infected by ZIKV are asymptomatic, but they can still 
develop complications that lead the patient to death or generate severe chronic conditions 
such as Guillain-Barré syndrome. Asymptomatic individuals may be important for sustain-
ing ZIKV transmission within a population despite being undiagnosed as a ZIKV case [6, 20].
Individuals with acute, symptomatic cases (25%) experience fever (elevation of axillary body tem-
perature greater than 37.2°C), nonpurulent conjunctivitis, headache, myalgia, arthralgia, asthenia, 
maculopapular rash (usually in extremities and trunk) (Figure 1), lower limb edema and less fre-
quently, retro-orbital pain, and gastrointestinal disturbance such as abdominal pain, nausea, and 
diarrhea. Notwithstanding, afebrile patients with rash should also be assessed for ZIKV infection 
[3, 11, 12]. These relatively mild symptoms last a few days (4–7 days), uncommonly result in 
hospitalization and are hardly distinguishable from other, better-known disease caused by other 
arboviruses [7, 16, 21]. Some neurological manifestations including  Guillain-Barré  syndrome, 
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acute myelitis, and meningoencephalitis are associated with detection of ZIKV in the cerebro-
spinal fluid [2, 16, 22]. Interestingly, this virus can cross the fetoplacental barrier to affect the 
fetus and cause microcephaly, microcephaly-related intellectual disabilities to neonates, ophthal-
mological alterations, loss hearing and epilepsy. Evidence has suggested that ZIKV could also 
invade cardiac cells, which could explain a described association between congenital heart dis-
ease in an infant born to a ZIKV-infected mother [13, 23, 24]. Differentiation on clinical grounds 
alone is often a very difficult task. The biological and clinical behaviors exhibit not only different 
characteristics but also great similarities; thus, ZIKV could be easily confused with other arbovi-
ruses. The clinical picture may be further complicated by coinfections with various combinations 
of arboviruses [9, 12, 18].
4. Diagnostics
The transmission of the diseases through mosquito bite is the most common scenario in ZIKV 
infection, which was described in 1966 in Malaysia. However, few cases of nonvector-borne 
infections have been reported, and the existence of ZIKV in the pharynx and saliva of infected 
patients represents a potential but unproven route of transmission. ZIKV also has been 
detected in semen, cervicovaginal fluid and urine, consistent with several well-documented 
cases of sexual transmission [3, 14, 16, 25].
The diagnosis of ZIKV infection is established through detection of ZIKV RNA by reverse 
transcription polymerase chain reaction (RT-PCR) typically performed on serum, plasma 
or urine within 2 weeks of symptom onset. ZIKV can also be diagnosed by serology (IgM 
Figure 1. Clinical aspects of patients with Zika virus infection (confirmed by PCR) (pictures took and provided with 
patient authorization, by co-author Jose Antonio Suarez, Instituto Gorgas, Panama): conjunctivitis, rash, arthralgia.
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antibodies). Serum RT-PCR is positive if done in the acute phase of the viremia, in blood on 
the first 3–7 days of the onset of illness, and for up to 10–14 days in urine. Enzyme-linked 
immunosorbent assay (ELISA) is used to detect IgM, but unfortunately, there are only a few 
laboratories able to perform an ELISA for ZIKV. Fewer laboratories still are able to perform 
neutralization assays, which may be more specific than ELISA, but require greater resources 
and biosafety containment. Although the specific antibodies against ZIKV in serum (IgM 
antibodies) are detectable after 4 days of symptom onset, its diagnostic value is limited due 
to cross-reactivity with other flaviviruses. Comparing relative titers of binding or neutraliz-
ing antibodies may be helpful in discriminating ZIKV from related flaviviruses like dengue 
in research settings, this is not yet standardized to aid in clinical diagnosis [16, 21].
The probable modes of perinatal transmission are transplacental or may occur during 
delivery. Concern has raised about the possibility of breastfeeding transmission. Prenatal 
fetal evaluation of pregnant women suspected or confirmed to have a ZIKV infection is 
done by regular fetal ultrasound examination, which can detect abnormalities as early as 
18–20 weeks of gestation. The main ultrasound findings associated with fetal ZIKV infection 
are microcephaly, intracranial calcifications, hydranencephaly, ventricular dilatation, brain 
atrophy, anhydramnios, hydrops fetalis, and intrauterine growth retardation. Amniotic fluid 
obtained by amniocentesis after 15 weeks of gestation can be tested for the presence of viral 
RNA by RT-PCR, but the sensitivity and specificity is unknown during gestation [13, 21, 26].
It is important in the differential diagnosis of dengue and chikungunya, among other condi-
tions such as malaria, leptospirosis, measles, and also to consider the possibility of coinfec-
tions, especially in endemic areas where all these pathogens can cocirculate simultaneously. 
During the symptomatic period of infection, various laboratory parameters provide informa-
tion on ZIKV infection. Various laboratory parameters such as leucopenia, thrombocytope-
nia, serum lactate dehydrogenase, gamma glutamyl transferase and elevated protein markers 
may be suggestive of ZIKV infection, but these findings are nonspecific [4, 13, 26]. Also, the 
virus can be detected in semen up to 81 days after infection.
5. Treatment
Currently, there is no ZIKV vaccine available, but the WHO has made ZIKV vaccine develop-
ment a top priority. Thus, more than 50 ZIKV vaccine candidates are now in various stages of 
research and development, mainly, in phase I/II clinical trials that include inactivated whole 
viruses, recombinant measles viral vector-based vaccines, DNA and mRNA vaccines, and a 
mosquito salivary peptide vaccine [17, 27].
The treatment for ZIKV infection is entirely supportive, no antiviral. No drugs have yet been 
approved for a specific ZIKV treatment, although numerous nucleoside analogs have some 
antiviral activities in cell cultures such as ribavirin, sofosbuvir or favipiravir. Acetaminophen 
is used to control fever and pain, avoiding aspirin or nonsteroidal anti-inflammatory drugs, 
because of their risk of hemorrhage (in case of DENV infection), and fluids are generously 
administered to prevent dehydration [24, 26, 28].
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6. Control and prevention
During the last few decades, Latin America has been threatened by an unprecedented explo-
sion of emerging arboviral outbreaks. These epidemics of emerging and re-emerging arbovi-
ruses are due to a number of factors such as climate change, levels of urbanization, increasing 
international travel, foreign trade, poor socioeconomic conditions, susceptible geographical 
areas (tropical and subtropical regions) among other factors. The presence of Aedes mosquitos 
enables ZIKV to invade new areas and poses a worldwide risk as there are no preventive 
approaches or vaccines for ZIKV [9, 12, 16, 26].
In countries where ZIKV epidemics are reported, cost-effectiveness studies may be important 
to determine the feasibility of systematic screening of blood components in donated samples. 
Unfortunately, at the moment, no specific data are available on the rate of reduction of blood-
borne transmission due to such practices. Because the prevalence of viremia in blood donations 
is high in endemic areas, mainly asymptomatic donors, donor selection professionals should 
carefully evaluate the appropriateness of the donation based on the patient’s background, like-
wise, follow up on donors with the aim of identifying the onset of symptoms [16, 26].
The most challenging aspect of ZIKV is preventing congenital infection. Recommendations 
to avoid mosquito exposure or avoid pregnancy altogether are not practical for most women 
living in ZIKV-endemic areas. Women who are or are planning to become pregnant are dis-
couraged from visiting areas of ZIKV transmission by travel restrictions issued by the US 
Center for Disease Control and other public health institutions. For preventing the sexual 
transmission of ZIKV for couples in which a man has traveled to or resides in an area with 
active ZIKV transmission, safe sexual practices for 6 months after the exposure regardless of 
the appearance of symptoms are recommended. What constitutes totally safe sexual practice 
is unclear, and some studies suggest that transmission of the small ZIKV (40 nm) may not be 
fully prevented by condoms [1, 2, 26, 29].
Much work remains before effective antiviral drugs and vaccines are available for ZIKV. For 
the time being, recognizing the importance of epidemiological control of emerging viral dis-
eases and taking preventive measures such as the increase in Aedes vector control and contain-
ment strategies guided by the scientific literature is a priority to achieve control of tropical 
viruses with epidemic potential [2, 3, 9]. In general, in countries with sporadic imported cases 
of ZIKV infection or in ZIKV-free countries, the only precaution that must be taken is to notify 
the cases. However, for epidemic areas, the main way to combat ZIKV is to cover skin by 
cloths, use mosquito repellents, reside in air-conditioned or screened rooms, and avoid being 
near water containers like stagnant water ponds, old automobile tire or plants containing 
water [16, 17, 26].
Finally, it is important to note that because only symptomatic individuals are diagnosed 
with ZIKV, robust epidemiologic data required for optimal control programs are lacking. 
Additionally, only a few reported cases have received laboratory confirmation; thus, condi-
tions such as dengue, chikungunya, malaria, leptospirosis, measles, among others may be 
incorrectly identified as ZIKV (or vice versa).
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